NASDAQ:OLMA Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis $12.05 0.00 (0.00%) Closing price 08/7/2026 04:00 PM EasternExtended Trading$11.88 -0.18 (-1.45%) As of 07:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Olema Pharmaceuticals Stock (NASDAQ:OLMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Olema Pharmaceuticals alerts:Sign Up Key Stats Today's Range$11.87▼$12.2150-Day Range$9.19▼$12.7752-Week Range$4.47▼$36.26Volume757,195 shsAverage Volume893,123 shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$44.10Consensus RatingModerate Buy Company Overview Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Read More Olema Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreOLMA MarketRank™: Olema Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 543rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingOlema Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialOlema Pharmaceuticals has a consensus price target of $44.10, representing about 266.0% upside from its current price of $12.05.Amount of Analyst CoverageOlema Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Olema Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.22) to ($2.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Olema Pharmaceuticals is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Olema Pharmaceuticals is -5.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOlema Pharmaceuticals has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Olema Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.77% of the float of Olema Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOlema Pharmaceuticals has a short interest ratio ("days to cover") of 11.29, which indicates bearish sentiment.Change versus previous monthShort interest in Olema Pharmaceuticals has recently increased by 7.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOlema Pharmaceuticals does not currently pay a dividend.Dividend GrowthOlema Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.58 News SentimentOlema Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Olema Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $144,750.00 in company stock.Percentage Held by Insiders12.56% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Olema Pharmaceuticals' insider trading history. Receive OLMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OLMA Stock News HeadlinesOlema Pharmaceuticals (OLMA) Expected to Post Earnings on MondayAugust 9 at 2:26 AM | americanbankingnews.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of "Moderate Buy" from AnalystsAugust 5, 2026 | americanbankingnews.comChina is not hedging. It's escaping.China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low. Beijing's central bank has bought gold for 20 straight months, its longest streak in a decade. Goldman Sachs estimates China's real gold buying is 4.8 times the official figure. The European Central Bank confirms gold has overtaken US Treasuries as the world's top reserve asset, at 27% versus 22%. As foreign demand for US debt fades, rates and everyday costs may feel the pressure.August 10 at 1:00 AM | Behind the Markets (Ad)Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Olema Pharmaceuticals (OLMA)July 14, 2026 | theglobeandmail.comDoes Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?June 30, 2026 | finance.yahoo.comHow Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer BetJune 17, 2026 | insidermonkey.comOlema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comSee More Headlines OLMA Stock Analysis - Frequently Asked Questions How have OLMA shares performed this year? Olema Pharmaceuticals' stock was trading at $25.00 at the start of the year. Since then, OLMA stock has decreased by 51.8% and is now trading at $12.05. How were Olema Pharmaceuticals' earnings last quarter? Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.52) EPS for the quarter, hitting the consensus estimate of ($0.52). When did Olema Pharmaceuticals IPO? Olema Pharmaceuticals (OLMA) raised $187 million in an IPO on Thursday, November 19th 2020. The company issued 11,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO. Who are Olema Pharmaceuticals' major shareholders? Top institutional shareholders of Olema Pharmaceuticals include BlackRock Inc. (7.69%), Hennion & Walsh Asset Management Inc. (0.48%), Bank of New York Mellon Corp (0.25%) and Deutsche Bank AG (0.11%). Insiders that own company stock include Bain Capital Life Sciences Inv, Bvf Partners L P/Il, Biocapital Advisors L Paradigm, Cyrus Harmon, David C Myles, Sean Bohen, Shane William Charles Kovacs, Naseem Zojwalla, Shawnte Mitchell and Ian T Clark. View institutional ownership trends. How do I buy shares of Olema Pharmaceuticals? Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Olema Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Olema Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings5/12/2026Today8/10/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 OLMA's financial health is in the Red zone, according to TradeSmith. OLMA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:OLMA CIK1750284 Webwww.olema.com Phone650-243-5555FaxN/AEmployees70Year Founded2007Price Target and Rating Average Price Target for Olema Pharmaceuticals$44.10 High Price Target$62.00 Low Price Target$27.00 Potential Upside/Downside+266.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$162.45 million Net MarginsN/A Pretax MarginN/A Return on Equity-46.00% Return on Assets-41.22% Debt Debt-to-Equity Ratio0.01 Current Ratio10.88 Quick Ratio10.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.88 per share Price / Book2.05Miscellaneous Outstanding Shares87,350,000Free Float76,376,000Market Cap$1.05 billion OptionableOptionable Beta2.03 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:OLMA) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock tomorrowA new strategy called Sell This, Buy That aims to help investors rotate out of overpriced AI stocks before a p...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredTrump's Next Move Could Shrink Your DollarThere's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...Priority Gold | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OLMA Stock Alerts